+7.1%
CRM vs MRNA
+511.3%
-504.2%
-43.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.0% | -2.2% | +0.3% | -1.9% |
| 7D | +1.3% | +5.5% | -4.2% | +1.1% |
| 30D | +34.3% | +158.7% | -124.4% | +28.6% |
| 3M | +37.7% | +182.1% | -144.4% | +31.8% |
| 6M | +34.9% | +151.8% | -116.9% | +30.3% |
| YTD | -1.6% | +393.6% | -395.2% | -10.5% |
| 1Y | +7.1% | +499.5% | -492.3% | -7.4% |
| All | +7.1% | +511.3% | -504.2% | -7.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling